VEGFA and myocardial infarction: It has been reported that hAMSCs significantly reduced the size of atherosclerotic lesions by inhibiting immune response via NF-κB pathway in mouse model [196] and improved left ventricular function, increased capillary density and the levels of angiogenic cytokine, angiopoetin (Ang)-1 and vascular endothelial growth factor (VEGF-A) in myocardial infarction [197,198] and decreased myocardial fibrosis area in ischemic heart tissue [199].